Dr  Guy Cameron

Dr Guy Cameron

Indigenous Imaging Fellow

School of Psychological Sciences

Career Summary

Biography

I'm a proud Aboriginal man; my mob are the Wailwan people, I have strong family connection with Wongaibon and Dainggatti. I'm an early career researcher (ECR) investigating fundamentals of immunology and microbiology in various tissues and disease states. My initial laboratory research focused on understanding the role of immune pathways in the development of respiratory disease, such as asthma and COPD, using pre-clinical models. This work led to several co-authored publications in top journals in the field for respiratory,  allergy and immunology research. This earlier work inspired my PhD in Immunology and Microbiology where I examined similar immune pathways using pre-clinical models of the urinary tract insult, such as sterile acute kidney injury and ascending bacterial urinary tract infection.


Since graduating from PhD studies, I have joined Professor Kelvin Kong’s research team, based at the Hunter Medical Research Institute (HMRI). Here I started investigating the biological properties of the bacterial species, Alloiococcus otitidis, which has a become a significant factor in the contemporary understanding of chronic ear infections. A further area of skill development has been conduction of a health audit with HMRI colleagues to gain a thorough understanding of respiratory admissions and Emergency Department presentations at hospitals across the Hunter New England Local Health District (HNELHD), based on the ICD-10 hospital codes. I also hold a fellowship supervised by Professor Michael Breakspear which is co-funded by the national imaging facility and systems neuroscience group to foster Indigenous collaboration and ownership in the field of imaging research to improve the health and wellbeing of Indigenous Australians.

In addition to my research activities, I take my heritage as an Aboriginal researcher seriously. As Chair of the Indigenous Student Engagement Committee, I seek opportunities to promote educational opportunities for upcoming Indigenous scholars. This includes tutoring and lecturing at the University of Newcastle and maintaining strong links to the team at the Wollotuka Institute, supporting for Indigenous activities. Additionally, I am a member of the Animal Care and Ethics Committee.




Vision

I aim to be able to utilise both basic and clinical expertise in the future to assemble a multi-disciplinary team to tackle major health challenges, specifically for Aboriginal and Torres Strait Islander people. Although early in my career, I have a strong commitment to improving healthcare using a biomedical, clinical and community driven approach.


Qualifications

  • Doctor of Philosophy in Immunology and Microbiology, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • Immunology
  • Microbiology

Languages

  • English (Mother)

Fields of Research

Code Description Percentage
450402 Aboriginal and Torres Strait Islander biomedical and clinical sciences 40
320402 Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies) 60

Professional Experience

UON Appointment

Title Organisation / Department
Casual Lecturer University of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
Microbiomic ECR Fellow University of Newcastle
School of Medicine and Public Health
Australia
Indigenous Imaging Fellow University of Newcastle
School of Psychological Sciences
Australia

Awards

Prize

Year Award
2021 Indigenous STEM Professional Career Achievement Award from the CSIRO and BHP Foundation
CSIRO - Commonwealth Scientific and Industrial Research Organisation

Teaching

Code Course Role Duration
INDH2490 Foundations of Aboriginal and Torres Strait Islander health
College of Health, Medicine & Wellbeing - The University of Newcastle
This course provides an opportunity for students to enhance their knowledge of historical and contemporary issues relevant to Aboriginal and Torres Strait Islander people.

This course will explore the tenets of culturally capable and safe health practice and its development by exploring the dynamics between Australia's health practice and contemporary social and healthcare policies, and the current health status for Aboriginal and Torres Strait Islander peoples.
Tutorial facilitator 1/1/2022 - 31/12/2022
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (7 outputs)

Year Citation Altmetrics Link
2022 Tu X, Kim RY, Brown AC, de Jong E, Jones-Freeman B, Ali MK, et al., 'Airway and parenchymal transcriptomics in a novel model of asthma and COPD overlap', Journal of Allergy and Clinical Immunology, 150 817-829.e6 (2022) [C1]

Background: Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases, and some patients have overlapping disease features, termed asthma-COP... [more]

Background: Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases, and some patients have overlapping disease features, termed asthma-COPD overlap (ACO). Patients characterized with ACO have increased disease severity; however, the mechanisms driving this have not been widely studied. Objectives: This study sought to characterize the phenotypic and transcriptomic features of experimental ACO in mice induced by chronic house dust mite antigen and cigarette smoke exposure. Methods: Female BALB/c mice were chronically exposed to house dust mite antigen for 11 weeks to induce experimental asthma, cigarette smoke for 8 weeks to induce experimental COPD, or both concurrently to induce experimental ACO. Lung inflammation, structural changes, and lung function were assessed. RNA-sequencing was performed on separated airway and parenchyma lung tissues to assess transcriptional changes. Validation of a novel upstream driver SPI1 in experimental ACO was assessed using the pharmacological SPI1 inhibitor, DB2313. Results: Experimental ACO recapitulated features of both asthma and COPD, with mixed pulmonary eosinophilic/neutrophilic inflammation, small airway collagen deposition, and increased airway hyperresponsiveness. Transcriptomic analysis identified common and distinct dysregulated gene clusters in airway and parenchyma samples in experimental asthma, COPD, and ACO. Upstream driver analysis revealed increased expression of the transcription factor Spi1. Pharmacological inhibition of SPI1 using DB2313, reduced airway remodeling and airway hyperresponsiveness in experimental ACO. Conclusions: A new experimental model of ACO featuring chronic dual exposures to house dust mite and cigarette smoke mimics key disease features observed in patients with ACO and revealed novel disease mechanisms, including upregulation of SPI1, that are amenable to therapy.

DOI 10.1016/j.jaci.2022.04.032
Citations Scopus - 7Web of Science - 2
Co-authors Kurtis Budden, Henry Gomez, Tattjhong Haw, Chantal Donovan, Alexandra Brown, Jay Horvat
2021 Loering S, Cameron GJM, Bhatt NP, Belz GT, Foster PS, Hansbro PM, Starkey MR, 'Differences in pulmonary group 2 innate lymphoid cells are dependent on mouse age, sex and strain', IMMUNOLOGY AND CELL BIOLOGY, 99 542-551 (2021) [C1]
DOI 10.1111/imcb.12430
Citations Scopus - 15Web of Science - 12
2019 Donovan C, Starkey MR, Kim RY, Rana BMJ, Barlow JL, Jones B, et al., 'Roles for T/B lymphocytes and ILC2s in experimental chronic obstructive pulmonary disease', Journal of Leukocyte Biology, 105 143-150 (2019) [C1]

Pulmonary inflammation in chronic obstructive pulmonary disease (COPD) is characterized by both innate and adaptive immune responses; however, their specific roles in the pathogen... [more]

Pulmonary inflammation in chronic obstructive pulmonary disease (COPD) is characterized by both innate and adaptive immune responses; however, their specific roles in the pathogenesis of COPD are unclear. Therefore, we investigated the roles of T and B lymphocytes and group 2 innate lymphoid cells (ILC2s) in airway inflammation and remodelling, and lung function in an experimental model of COPD using mice that specifically lack these cells (Rag1 -/- and Rora fl/fl Il7r Cre [ILC2-deficient] mice). Wild-type (WT) C57BL/6 mice, Rag1 -/- , and Rora fl/fl Il7r Cre mice were exposed to cigarette smoke (CS; 12 cigarettes twice a day, 5 days a week) for up to 12¿weeks, and airway inflammation, airway remodelling (collagen deposition and alveolar enlargement), and lung function were assessed. WT, Rag1 -/- , and ILC2-deficient mice exposed to CS had similar levels of airway inflammation and impaired lung function. CS exposure increased small airway collagen deposition in WT mice. Rag1 -/- normal air- and CS-exposed mice had significantly increased collagen deposition compared to similarly exposed WT mice, which was associated with increases in IL-33, IL-13, and ILC2 numbers. CS-exposed Rora fl/fl Il7r Cre mice were protected from emphysema, but had increased IL-33/IL-13 expression and collagen deposition compared to WT CS-exposed mice. T/B lymphocytes and ILC2s play roles in airway collagen deposition/fibrosis, but not inflammation, in experimental COPD.

DOI 10.1002/JLB.3AB0518-178R
Citations Scopus - 43Web of Science - 33
Co-authors Chantal Donovan, Jay Horvat, Kurtis Budden, Tattjhong Haw
2019 Cameron GJM, Jiang SH, Loering S, Deshpande AV, Hansbro PM, Starkey MR, 'Emerging therapeutic potential of group 2 innate lymphoid cells in acute kidney injury', Journal of Pathology, 248 9-15 (2019) [C1]

Acute kidney injury (AKI) remains a global challenge and, despite the availability of dialysis and transplantation, can be fatal. Those that survive an AKI are at increased risk o... [more]

Acute kidney injury (AKI) remains a global challenge and, despite the availability of dialysis and transplantation, can be fatal. Those that survive an AKI are at increased risk of developing chronic kidney disease and end stage renal failure. Understanding the fundamental mechanisms underpinning the pathophysiology of AKI is critical for developing novel strategies for diagnosis and treatment. A growing body of evidence indicates that amplifying type 2 immunity may have therapeutic potential in kidney injury and disease. Of particular interest are the recently described subset of innate immune cells, termed group 2 innate lymphoid cells (ILCs). Group 2 ILCs are crucial tissue-resident immune cells that maintain homeostasis and regulate tissue repair at multiple organ sites, including the kidney. They are critical mediators of type 2 immune responses following infection and injury. The existing literature suggests that activation of group 2 ILCs and production of a local type 2 immune milieu is protective against renal injury and associated pathology. In this review, we describe the emerging role for group 2 ILCs in renal homeostasis and repair. We provide an in-depth discussion of the most recent literature that use preclinical models of AKI and assess the therapeutic effect of modulating group 2 ILC function. We debate the potential for targeting these cells as novel cellular therapies in AKI and discuss the implications for future studies and translation. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

DOI 10.1002/path.5242
Citations Scopus - 15Web of Science - 13
2019 Starkey MR, Plank MW, Casolari P, Papi A, Pavlidis S, Guo Y, et al., 'IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis', EUROPEAN RESPIRATORY JOURNAL, 54 (2019) [C1]
DOI 10.1183/13993003.00174-2018
Citations Scopus - 53Web of Science - 37
Co-authors Gerard Kaiko, Jay Horvat, Chantal Donovan, Tattjhong Haw
2019 Cameron GJM, Cautivo KM, Loering S, Jiang SH, Deshpande AV, Foster PS, et al., 'Group 2 Innate Lymphoid Cells Are Redundant in Experimental Renal Ischemia-Reperfusion Injury', Frontiers in Immunology, 10 (2019) [C1]
DOI 10.3389/fimmu.2019.00826
Citations Scopus - 26Web of Science - 20
2019 Loering S, Cameron GJM, Starkey MR, Hansbro PM, 'Lung development and emerging roles for type 2 immunity', Journal of Pathology, 247 686-696 (2019) [C1]

Lung development is a complex process mediated through the interaction of multiple cell types, factors and mediators. In mice, it starts as early as embryonic day 9 and continues ... [more]

Lung development is a complex process mediated through the interaction of multiple cell types, factors and mediators. In mice, it starts as early as embryonic day 9 and continues into early adulthood. The process can be separated into five different developmental stages: embryonic, pseudoglandular, canalicular, saccular, and alveolar. Whilst lung bud formation and branching morphogenesis have been studied extensively, the mechanisms of alveolarisation are incompletely understood. Aberrant lung development can lead to deleterious consequences for respiratory health such as bronchopulmonary dysplasia (BPD), a disease primarily affecting preterm neonates, which is characterised by increased pulmonary inflammation and disturbed alveolarisation. While the deleterious effects of type 1-mediated inflammatory responses on lung development have been well established, the role of type 2 responses in postnatal lung development remains poorly understood. Recent studies indicate that type 2-associated immune cells, such as group 2 innate lymphoid cells and alveolar macrophages, are increased in number during postnatal alveolarisation. Here, we present the current state of understanding of the postnatal stages of lung development and the key cell types and mediators known to be involved. We also provide an overview of how stem cells are involved in lung development and regeneration, and the negative influences of respiratory infections. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

DOI 10.1002/path.5211
Citations Scopus - 24Web of Science - 16
Show 4 more journal articles
Edit

Grants and Funding

Summary

Number of grants 12
Total funding $3,248,604

Click on a grant title below to expand the full details for that specific grant.


20242 grants / $601,305

From community priority to delivery of care: Co-designing effective treatment models for Aboriginal women with asthma during pregnancy$599,305

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Elissa Jane Elvidge, Karen Baker, Doctor Guy Cameron, Doctor Tameka McFadyen, Kim Morey, Louise Morris, Associate Professor Vanessa Murphy, Professor Peter O'Mara, Ms Shanthi Ramanathan, Associate Professor Geraint Rogers, Professor Juanita Sherwood, Doctor Meredith Tavener, Dr Steven Taylor, Ms Yeena Thompson, Professor Peter Wark
Scheme MRFF - PPHRI - Consumer-Led Research
Role Investigator
Funding Start 2024
Funding Finish 2026
GNo G2300814
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON Y

Indigenisation of the undergraduate curriculum in biomedical science, pharmacy and sport science: Consultation with Indigenous stakeholders$2,000

Funding body: Learning Design and Teaching Innovation | The University of Newcastle

Funding body Learning Design and Teaching Innovation | The University of Newcastle
Project Team

Professor Karen Mate, Doctor Lizzie Manning, Doctor Guy Cameron, Doctor Sajie Endacott, Ms Sharleen Slater

Scheme Teaching and Learning Seed Funding
Role Investigator
Funding Start 2024
Funding Finish 2024
GNo
Type Of Funding Internal
Category INTE
UON N

20234 grants / $2,527,629

A treatable traits framework for chronic respiratory disease in rural and regional Aboriginal communities$1,997,629

Funding body: Medical Research Futures Fund (MRFF)

Funding body Medical Research Futures Fund (MRFF)
Project Team

Professor Geraint Rogers, Professor Peter Wark, Professor Jodie Simpson, Doctor Steven Taylor, Doctor Guy Cameron, Doctor Elissa Elvidge, Ms Erin Flynn, Professor Caroline Miller, Professor Steven Wesselingh, Mr Paul Duncan, A/Professor Odette Pearson, Ms Karen Baker, A/Professor Penny Reeves.

Scheme 2021 MRFF Chronic Respiratory Conditions
Role Investigator
Funding Start 2023
Funding Finish 2028
GNo
Type Of Funding C1300 - Aust Competitive - Medical Research Future Fund
Category 1300
UON N

Genomic surveillance of bacterial strains causing ear disease and upper respiratory illnesses in Hunter New England children and young people$500,000

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Doctor Guy Cameron, Doctor Trent Butler, Professor Kelvin Kong, Doctor Hemalatha Varadhan, Ms Sharron Hall, Doctor Michael Zhang, Professor Joerg Mattes, Doctor Christopher Ashhurst-Smith, Ms Toni Manton, Mr Trumaine Rankmore, Dr Trent Butler
Scheme Early-Mid Career Researcher Grant
Role Lead
Funding Start 2023
Funding Finish 2026
GNo G2300019
Type Of Funding C2400 – Aust StateTerritoryLocal – Other
Category 2400
UON Y

Seeds of growth and healing: Exploring the healing properties of Indigenous native plants$15,000

Funding body: The University of Newcastle and the University of Waikato

Funding body The University of Newcastle and the University of Waikato
Project Team

Ms Jennifer Rumbel, Doctor Guy Cameron, Doctor Robert Chapman, Professor Michael Breakspear, A/Professor Saad Ramadan, Professor Hubert Hondermarck, Mr John Clarke; Doctor Mitchell Head, A/Professor Maui Hudson, Doctor Rogena Sterling, A/Professor Pawel Olszewski, Ms Katie-Lee Riddle

Scheme Partnership Seed Fund | The University of Newcastle and the University of Waikato
Role Investigator
Funding Start 2023
Funding Finish 2023
GNo
Type Of Funding Internal
Category INTE
UON N

Enhancing Indigenous cultural capability and student engagement in science and health through collaborative learning and animated videos$15,000

Funding body: The University of Newcastle and the University of Waikato

Funding body The University of Newcastle and the University of Waikato
Project Team

Ms Josephine Smith, A/Professor Kathryn Skelding, A/Professor Karen Mate, Doctor Lizzie Manning, Doctor Guy Cameron, Mr Paul McDonald, Ms Andrea Windley, Doctor Joanna Hicks, Doctor Kim Hebert-Losier, Ms Nicole Pepperell, Doctor Kirsten Petrie, Ms Jessicca Usu, Doctor Gloria Hinemoa Clarke

Scheme Partnership Seed Fund | The University of Newcastle and the University of Waikato
Role Investigator
Funding Start 2023
Funding Finish 2023
GNo
Type Of Funding Internal
Category INTE
UON N

20222 grants / $15,670

Establishing laboratory methodology for Indigenous ear disease; Advanced studies of the role of Alloiococcus otitidis in Aboriginal and Torres Strait children with otitis media$10,000

Funding body: College of Health, Medicine and Wellbeing, University of Newcastle

Funding body College of Health, Medicine and Wellbeing, University of Newcastle
Project Team

Doctor Guy Cameron, Doctor Christopher Ashhurst-Smith, Doctor Karl Hassan, Professor Kelvin Kong, Ms Sharron Hall

Scheme College of Health, Medicine and Wellbeing Strategic Research Pilot Grant round
Role Lead
Funding Start 2022
Funding Finish 2022
GNo
Type Of Funding Internal
Category INTE
UON N

Audit of Hunter New England ear, nose & throat surgical interventions$5,670

Funding body: Immune Health Program, Hunter Medical Research Institute

Funding body Immune Health Program, Hunter Medical Research Institute
Project Team

Doctor Guy Cameron, Professor Kelvin Kong, Ms Sharron Hall

Scheme Immune Health Program Small Grant scheme for HMRI Platform Support
Role Lead
Funding Start 2022
Funding Finish 2022
GNo
Type Of Funding Internal
Category INTE
UON N

20181 grants / $98,000

Understanding the role of group 2 innate lymphoid cells and mucosal cytokines in urinary tract injury and infection$98,000

Funding body: Australian Government, Department of Education, Skills, and Employment

Funding body Australian Government, Department of Education, Skills, and Employment
Project Team

Doctor Guy Cameron, Doctor Malcolm Starkey, Doctor Aniruddh Deshpande, Professor Philip Hansbro, A/Professor Adam Collison

Scheme Research Training Program
Role Lead
Funding Start 2018
Funding Finish 2021
GNo
Type Of Funding C1700 - Aust Competitive - Other
Category 1700
UON N

20171 grants / $2,000

Understanding the role of group 2 innate lymphoid cells in the kidney$2,000

Funding body: PRC GrowUpWell

Funding body PRC GrowUpWell
Project Team

Doctor Guy Cameron, Doctor Malcolm Starkey, Doctor Aniruddh Deshpande, Professor Philip Hansbro

Scheme PRC GrowUpWell Honours Research Internship
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding Internal
Category INTE
UON N

20161 grants / $2,000

Understanding how immune cells repair the kidney after acute kidney injury$2,000

Funding body: School of Biomedical Sciences and Pharmcy, The University of Newcastle

Funding body School of Biomedical Sciences and Pharmcy, The University of Newcastle
Project Team

Doctor Guy Cameron, Doctor Malcolm Starkey, Doctor Aniruddh Deshpande

Scheme School of Biomedical Sciences and Pharmacy Vacation Scholarship
Role Lead
Funding Start 2016
Funding Finish 2017
GNo
Type Of Funding Internal
Category INTE
UON N

20151 grants / $2,000

Transcriptome analysis of developing mouse lung following early life infection$2,000

Funding body: School of Biomedical Sciences and Pharmcy, The University of Newcastle

Funding body School of Biomedical Sciences and Pharmcy, The University of Newcastle
Project Team

Doctor Guy Cameron, Doctor Malcolm Starkey, Professor Philip Hansbro

Scheme School of Biomedical Sciences and Pharmacy Vacation Scholarship
Role Lead
Funding Start 2015
Funding Finish 2016
GNo
Type Of Funding Internal
Category INTE
UON N
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 7
United Kingdom 3
Canada 2
United States 2
Italy 1
Edit

News

infectious ear and upper respiratory disease

News • 31 Jul 2023

$1m supports immunology and microbiology researchers

Two Newcastle scientists are among six promising researchers recognised with a prestigious NSW Government grant designed to support and build health and medical research talent in NSW.

Dr Guy Cameron

Positions

Indigenous Imaging Fellow
School of Psychological Sciences
College of Engineering, Science and Environment

Microbiomic ECR Fellow
School of Medicine and Public Health
College of Health, Medicine and Wellbeing

Casual Lecturer
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing

Contact Details

Email guy.cameron@newcastle.edu.au
Phone (02) 4913 8070
Links Personal webpage
Twitter

Office

Building HMRI building
Location John Hunter Hospital campus

,
Edit